Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
First Claim
Patent Images
1. A pharmaceutical composition product comprising:
- a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and;
b. an actuator able to produce an aerosol of said solution, wherein the spray pattern ellipticity ratio of said aerosol is between 1.00 and 1.40 when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip.
6 Assignments
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions and methods are described comprising at least one Y2 receptor-binding peptide, such as peptide YY(PYY), Neuropeptide Y (NPY) or Pancreatic Peptide (PP) and one or more mucosal delivery-enhancing agents for enhanced nasal mucosal delivery of the peptide YY, for treating a variety of diseases and conditions in mammalian subjects, including obesity.
-
Citations
16 Claims
-
1. A pharmaceutical composition product comprising:
-
a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and;
b. an actuator able to produce an aerosol of said solution, wherein the spray pattern ellipticity ratio of said aerosol is between 1.00 and 1.40 when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip. - View Dependent Claims (2, 3, 4, 5, 6, 8)
-
-
7. A pharmaceutical composition product comprising:
-
a. an aqueous solution of a Y2 receptor binding compound;
b. an actuator to produce an aerosol of said solution, wherein the spray pattern major and minor axes of said aerosol are between 10 and 50 mm when measured at a height of between 0.5 cm and 10 cm distance from the actuator tip. - View Dependent Claims (9, 10, 12, 13)
-
-
11. A pharmaceutical composition product comprising:
-
a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and;
b. an actuator to produce an aerosol of said solution, wherein less than 10% of the droplets are smaller than 10 microns in size. - View Dependent Claims (14)
-
-
15. A pharmaceutical composition product comprising:
-
a. an aqueous solution formulation of a Y2 receptor binding compound at a concentration sufficient to produce therapeutically effective plasma concentrations and;
b. an actuator selected to produce an aerosol of said solution, wherein droplets between 25 and 700 microns are produced. - View Dependent Claims (16)
-
Specification